1. The following typo has been corrected in recommendation 7 (part 7, recommendation 10 in the online supplement):
If the patient is aged ≥ 65 years or the CHADS 2 score ≥ 1, we suggest that clopidogrel 75 mg/d and OAC be given, without concomitant ASA, for 12 months post-PCI (Conditional Recommendation, Moderate-Quality Evidence), to be followed by OAC alone (Strong Recommendation, High-Quality Evidence). 3. Figure 2 has been updated to include a footnote that states "Primary CAD prevention with ASA may be considered in selected high-risk patients". Please see revised figure 2 on the following pages.
We deeply apologize for these errors.
Revised The procedural/ surgical risk categorization list may be updated based on new information, and can be found at Thrombosis Canada (http://thrombosiscanada.ca)
Revised Figure 2 : A summary of our recommendations for the management of antithrombotic therapy in patients with concomitant atrial fibrillation (AF) and an indication for primary coronary artery disease (CAD) prevention or stable CAD/arterial vascular disease. ASA, acetylsalicylic acid (aspirin); CHADS2, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; NOAC, nonvitamin K antagonist oral anticoagulant; OAC, oral anticoagulant.
